Nymox Pharmaceutical Corporation (NYMXF)
OTCMKTS · Delayed Price · Currency is USD
0.0320
-0.0036 (-10.11%)
Oct 1, 2026, 4:00 PM EST

Nymox Pharmaceutical Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-4.28-4.49-8.84-6.58-12.54
Depreciation & Amortization
0.1300.170.250.23
Stock-Based Compensation
1.710.673.360.592.6
Other Operating Activities
--0.440.030.02
Change in Accounts Payable
0.631.241.320.38-0.17
Change in Other Net Operating Assets
0.01-0.02-0.50.120.03
Operating Cash Flow
-1.81-2.6-4.06-5.21-9.82
Operating Cash Flow Growth
-----

Investing Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-0--0--0.01
Investing Cash Flow
-0--0--0.01

Financing Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
1.742.671.75--
Total Debt Issued
1.742.671.75--
Long-Term Debt Repaid
--0.06-0.17-0.23-0.24
Lease Payments
--0.06-0.17-0.23-0.24
Net Debt Issued (Repaid)
1.742.611.58-0.23-0.24
Issuance of Common Stock
--1.154.276.95
Other Financing Activities
---1.740.33
Financing Cash Flow
1.742.612.735.787.05

Net Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
-0.070-1.330.57-2.78

Free Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-1.81-2.6-4.06-5.21-9.83
Free Cash Flow Growth
-----
Free Cash Flow Per Share
-0.02-0.03-0.04-0.06-0.12
Levered Free Cash Flow
-0.67-1.32-1.12-2.81-5.15
Unlevered Free Cash Flow
-0.3-1.18-1.08-2.79-5.12
Free Cash Flow After Leases
-1.81-2.67-4.23-5.43-10.06

Additional Metrics

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Change in Working Capital
0.641.220.820.5-0.14